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Abstract
Background and objectivesWomen affected by CKD increasingly choose to get pregnant. Experience with low-
protein diets is limited. The aim of this studywas to review results obtained from pregnant womenwith CKD on
supplemented vegan–vegetarian low-protein diets.
Design, setting, participants, &measurements Thiswas a single-arm, open intervention study between 2000–2012
of a low-protein diet in pregnant patients with stages 3–5 CKD or severe proteinuria (.1 g/d in the first trimester
or nephrotic at any time). Stages 3–5 CKD patients whowere not on low-protein diets for clinical, psychologic, or
logistic reasons served as controls. The setting was the Obstetrics-Nephrology Unit dedicated to kidney diseases
in pregnancy. The treated group included 24 pregnancies—21 singleton deliveries, 1 twin pregnancy, 1 abortion,
and 1 miscarriage. Additionally, there were 21 controls (16 singleton deliveries, 5 miscarriages). The diet was
a vegan–vegetarian low-protein diet (0.6–0.8 g/kg per day) with keto-acid supplementation and 1–3 protein-
unrestricted meals allowed per week.
Results Treated patients and controls were comparable at baseline for median age (35 versus 34 years), referral
week (7 versus 8), eGFR (59 versus 54 ml/min), and hypertension (43.5% versus 33.3%); median proteinuria was
higher in patients on the low-protein diet (1.96 [0.1–6.3] versus 0.3 [0.1–2.0] g/d; P,0.001). No significant dif-
ferences were observed in singletons with regard to gestational week (34 versus 36) or Caesarean sections
(76.2% versus 50%). Kidney function at delivery was not different, but proteinuria was higher in the diet group.
Incidence of small for gestational age babies was significantly lower in the diet group (3/21) versus controls
(7/16; chi-squared test; P=0.05). Throughout follow-up (6 months to 10 years), hospitalization rates and preva-
lence of children below the third percentile were similar in both groups.
Conclusion Vegan–vegetarian supplemented low-protein diets in pregnant women with stages 3–5 CKD may
reduce the likelihood of small for gestational age babies without detrimental effects on kidney function or pro-
teinuria in the mother.
Clin J Am Soc Nephrol 9: ccc–ccc, 2014. doi: 10.2215/CJN.06690613
Introduction
In the era of epigenetics, the early phases of human
development are considered clues for future health
and disease. Reports of increased risk for intellectual
deficits, behavioral difficulties, and metabolic de-
rangements in small, underdeveloped, or premature
babies are gaining relevance (1–9).
However, the clinical applications of these epide-
miologic data are controversial because of the differ-
ent causes of small babies. The literature includes
studies on small babies (below 2,500 g at birth), small
for gestational age (SGA) babies (birth weight is re-
lated to gestational week, sex, and local birth weight
references), and fetal growth-restricted babies (in
which a previously harmonic growth is impaired by
a relevant pathologic event). These definitions partly
overlap, but only SGA and growth-restricted babies
have a definite pathologic meaning (8–13).
Children born to mothers with CKD are at higher
risk of being small and/or premature, and premature
children may display increased risk of CKD later in
life (14–18). Despite heterogeneous medical literature,
the overall risk of delivering small children parallels
CKD progression (16–20).
Thus, the success that has been achieved by im-
proving maternal–fetal outcomes in CKD women
may result in a paradoxical increase of CKD in their
offspring, with important clinical and ethical implica-
tions (21–23). In this context, therapeutic interven-
tions in pregnancy are crucial, and the attention is
shifting from short- to long-term effects.
Low-protein diets are pivotal for slowing down
CKD progression (24–26), and they may be prom-
ising tools for counterbalancing hyperfiltration
during pregnancy, which very often results in an
increase in proteinuria and functional impairment,
*SS Nephrology,
Department of
Clinical and
Biological Sciences,
San Luigi Hospital, and
†Gynecology and
Obstetrics 2U,
Department of
Surgical Sciences,
University of Turin,
Turin, Italy
Correspondence:
Dr. Giorgina B.
Piccoli, University of
Torino, san Luigi,
Clinical and
Biological Sciences,
Regione Gonzole,
Orbassano, Turin,
10100, Italy. Email:
gbpiccoli@yahoo.it
www.cjasn.org Vol 9 May, 2014 Copyright © 2014 by the American Society of Nephrology 1
 . Published on February 27, 2014 as doi: 10.2215/CJN.06690613CJASN ePress
particularly in patients with severe GFR reduction at
baseline.
Indeed, therapeutic approaches that presumably interact
with hyperfiltration may allow more babies to reach a later
pregnancy stage.
Although high-protein diets are increasingly discour-
aged during pregnancy, less is known about protein
restriction, such as in diets prescribed for CKD (27–30).
Our previous study on a small series of patients on sup-
plemented low-protein diets in pregnancy is one of the few
available studies (31). Our data were in line with other
reports on the advantages of vegetable proteins in reduc-
ing kidney disease progression rate in pregnant or lactat-
ing animals (31–33).
The aim of the present study was to review our
experience with low-protein vegan–vegetarian diets sup-
plemented by amino and keto acids in patients with stages
3–5 CKD or relevant proteinuria during pregnancy. In par-
ticular, we focused our analysis on the following outcomes
in children: intrauterine growth, clinical problems, and for
older children, psychosocial development.
Materials and Methods
Definitions
CKD was defined and staged according to Kidney
Disease Outcomes Quality Initiative guidelines (Chronic
Kidney Disease Epidemiology Collaboration) and when-
ever possible, on the basis of preconception data. GFR and
proteinuria were assessed by 24-hour urine collections
throughout pregnancy (18,34).
Newborns were defined as SGA when birth weight was
below the 10th percentile according to Italian birth weight
references (35,36). Fetal growth restriction was defined as
flattening of the growth curve. Preterm delivery and early
preterm delivery were defined as deliveries occurring be-
fore 37 and 34 completed weeks of gestational age, respec-
tively. Apgar scores were recorded at 1 and 5 minutes by
neonatologists (18,34).
Intrauterine growth was assessed by calculating gesta-
tional age-adjusted percentiles and Z scores (35,36).
Study Setting and Control Policy
The study was performed at the Maternal-Fetal Medicine
Unit of Sant’Anna University Hospital, Turin, Italy. Data
were prospectively gathered from January 1, 2000, to De-
cember 31, 2012.
The frequency of nephrology and obstetric visits ranged
from one time per week to one time per month. Ultrasound
biometry was performed every 2–3 weeks for SGA babies or
those babies at risk for fetal growth restriction. All visits
were personalized as previously described (18,34,37). Cesar-
ean section was performed for fetal indications before or
during labor, cases of unfavorable conditions for induction
(e.g., prematurity), and lack of response to induction. In all
cases, the aim was to delay delivery until 34–36 weeks, de-
pending on fetal–maternal clinical conditions (18,34).
Low-Protein Diet
The diet was an adaptation of the low-protein vegan–
vegetarian diet prescribed at our center (38,39). Our diet
for nonpregnant patients is vegan, with a protein intake of
0.6 g/kg per day (ideal weight), one to three free meals per
week, and keto acid supplementation of 1 pill/8–10 kg
ideal BW (IBW) (31,40).
In an empirical attempt to balance the advantages of low-
protein diets in CKD and the habit of increasing protein
intake in pregnancy, we adjusted the diet in pregnancy to
0.6–0.8 g/kg per day protein based on preconception
weight (Supplemental Appendix). The basic diet was
vegan supplemented with a mixture of amino and keto
acids (commercially available in Italy as Alfa-kappa;
each 600-mg tablet contains calcium salts of hydroxyl
and keto analogs of isoleucine, leucine, phenylalanine, va-
line, methionine, and amino acids [i.e., lysine, threonine,
histidine, and tyrosine]).
We progressively allowed small quantities of milk and
yogurt (100–150 ml/d) for patients who would otherwise
have had difficulties reaching the target caloric intake
(hence, the definition of vegan–vegetarian). Although our
first patients received one tablet of keto acid for 8 kg IBW
during the first trimester and up to 1 tablet for 5 kg IBW in
the last trimester, we progressively adjusted the diet with a
more liberal allowance of vegetable proteins, reducing the
supplementation to 1 tablet per 8–10 kg IBW (31). In the
absence of reports about specific keto and amino acid mix-
tures in pregnancy, efforts were made to check for risks
linked to protein content and additives. At the time of the
present study, no reports on any of these issues had been
found or made available by the company (Fresenius Kabi).
On the basis of functional status, level of proteinuria, and
patients’ preferences, one to three free meals per week
were allowed (unrestricted with regard to both vegetable
and animal protein content, although still limiting unsat-
urated fats and sugars).
Caloric intake was controlled according to the current
indications in pregnancy, and it was targeted to about 30
kcal/kg per day considering IBW and the presence/
absence of diabetes. In addition to the standard biochem-
ical exams evaluating CKD, we progressively added iron
status, B12, 25-OH vitamin D, and electrolytes. Specific
supplements were prescribed on the basis of the biochem-
ical results. Erythropoietin was used as required, with a
hemoglobin target of 10 g/dl on account of the physiologic
hemodilution of pregnancy.
Patient Selection
During the study period, 383 pregnancies were referred
to us in patients with kidney diseases (stage 1, n=291; stage
2, n=55; stage 3, n=30; stage 4, n=6; stage 5, n=1).
The main indications for this type of diet were pregnancy
in patients on a supplemented vegetarian diet, severe CKD
(stages 3b–5), severe proteinuria (over 3 g/d or above
1 g/d in the first 20 weeks of gestation), previous ne-
phrotic syndrome, or a combination of any of these ele-
ments. Patients referred in the last phases of pregnancy or
for whom delivery was expected within less than 4 weeks
were not taken into consideration for this approach.
The diet was prescribed either at referral or after an
initial increase in serum creatinine or proteinuria based
on the above-mentioned criteria. Only patients who fol-
lowed the diet for at least 4 weeks before delivery or
pregnancy interruption were included in the present
study (Figure 1).
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Because the diet was routinely offered to all patients with
the above-mentioned characteristics, a strictly equivalent
control group was not available. Therefore, our control
group consisted of all consecutive subjects with stages 3–5
CKD carrying singletons who did not follow the diet for
personal, clinical, or logistic problems, excluding miscar-
riages or abortions occurring within 2 weeks from referral
(or in the first 12 weeks).
Follow-Up Information
Follow-up information for mothers who were still being
followed at our center or their nephrology center was
obtained during routine clinical visits, whereas for the few
patients who were not followed by a nephrology unit, it
was obtained by phone interview. The main clinical
problems, including hospitalizations, were also recorded.
Only two patients in the intervention group and five
patients in the control group were lost to long-term follow-
up. Follow-up at 3 months was available for all patients
who followed the diet and 13 of 16 patients who did not
follow the diet.
After delivery, growth analysis was performed accord-
ing to the international references (41–43).
Statistical Analyses
Descriptive analysis was performed as appropriate. Paired
t (pre- and postpregnancy data), t, chi-squared, Fisher’s, and
Wilcoxon’s tests were used for comparisons. Significance
was set at ,0.05. Statistical evaluation was performed using
SPSS, version 18.0, for Windows (SPSS, Chicago, IL).
Ethical Issues
Patients were informed that no data regarding the
supplemented diet during pregnancy were available,
with the exception of a previous report by our group
(for the patients who started the diet in the last 3 years) (31).
Patients were asked to provide informed consent to the
diet. The form stated the limits and goals of the diet and
the importance of timely reporting of any side effects pos-
sibly linked to the diet.
Neither the mothers nor the children underwent clinical,
blood, or urine tests for the sake of the present study, which
was purposely limited to recording the most important
growth patterns and the main clinical and/or develop-
mental outcomes.
The study was performed according to the principles of
the Declaration of Helsinki and approved by the ethics
committee of the Ospedale Infantile Regina Margherita
Sant’Anna Hospital–Ordine Mauriziano (number 335; pro-
tocol 11551/c28.2, 4/3/2011).
Results
Baseline Data
The main baseline data regarding 24 pregnancies in 22
patients who followed our low-protein diet are reported in
Table 1. Two patients had two pregnancies, one pregnancy
Figure 1. | Flow chart of cases and controls selection criteria. In total, 383 pregnancies were referred in patients with kidney diseases in the
study period (stage 1, n=291; stage 2, n=55; stage 3, n=30; stage 4, n=6; stage 5, n=1). Pregnancy terminations within 2 weeks from referral
were not considered in the present analysis.
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was voluntarily terminated, one patient miscarried, and
one pregnancy was a twin pregnancy. Thus, the 24 preg-
nancies resulted in 23 live-born babies.
Two patients were already on the diet before pregnancy,
whereas in the other cases, the diet was prescribed during
pregnancy. The main indications for the diet were almost
evenly divided between severe CKD and proteinuria.
Seven patients (eight pregnancies) were affected by type
1 diabetes (Table 1).
For the control group with 21 pregnancies, the main
reasons for not prescribing the diet during pregnancy were
stable kidney function (seven patients) and previous eating
disorders (three patients). Five miscarriages were recorded,
thus resulting in 16 live-born children for the analysis
(Table 1).
Despite the nonrandom selection of cases, the two
cohorts were comparable for age, referral week, kidney
function, prevalence of hypertension, and body mass
index, whereas because of the selection policy, proteinuria
was significantly higher in the low-protein diet patients
(P,0.001).
Pregnancy Outcomes: Kidney Function and Proteinuria
All patients in the intervention group were able to follow
the diet throughout pregnancy. No diet or supplementation
side effects were reported. On the basis of dietary recall, all
patients followed the diet with good compliance; the main
drawbacks were monotony and the need to account for the
double goal of low-protein diet and low weight gain
(maximum=10–12 kg).
As expected in a CKD population, the antihypertensive
drug requirement increased in both groups (Table 2). Hyper-
tension was the main reason for delivery in 6 of 22 cases in
the diet group and 2 of 16 cases in the control group (Table 3).
In the intervention group, one patient doubled serum
creatinine levels during pregnancy, and one patient in-
creased by one CKD stage (Table 2). Serum creatinine in-
creased significantly in the diet group during pregnancy
(P=0.02); the increase is not merely explained by the steep
rise in a single case (Figure 2).
Proteinuria increased significantly in both groups (diet:
P,0.01; controls: P=0.001) (Figure 2, Table 2). Despite the
increase in proteinuria, serum albumin and total proteins
were only moderately decreased. Proteinuria decreased af-
ter pregnancy in all but two cases.
No significant differences were observed between the
diet and control groups in week of delivery and kidney
function, whereas proteinuria remained higher and total
proteins and albumin remained lower in the diet group
(P=0.01) (Table 2).
Pregnancy Outcomes: Intrauterine Growth.
The prevalence of SGA babies was lower for mothers
who followed the diet: three singletons and one twin in the
diet group versus seven singletons in the nondiet group
(P=0.05 in singletons).
Of note, 8 of 10 SGA singletons were preterm (Table 3).
Cesarean section was performed preterm for maternal
reasons in 10 of 22 patients in the diet group and 5 of 16
patients in the control group. It was performed for fetal
reasons in 6 of 22 cases in the diet group and 4 of 16 cases in
the control group (P=1). The need for hospitalization in the
neonatal intensive care unit was higher in the diet group;
the difference did not reach statistical significance and was
presumably linked to the lower, albeit nonsignificantly
lower, gestational age.
Follow-Up Data
The main data regarding long-term follow-up of the
children (6 months to 10 years) are reported in Table 4. No
socialization or schooling problems were reported. Preva-
lence of hospitalization was similar in both groups (4 of 19
children in the diet group and 4 of 15 children in the control
group), and the prevalence of children below the third per-
centile was also similar (height, weight, or both: 4 of 19
children in the diet group versus 2 of 15 children in the
control group).
Discussion
The interaction between placental development, renal
hyperfiltration, increase in proteinuria, and development of
pregnancy-related hypertensive disorders is still not fully
understood (16–20). Because of their teratogenicity, the need
to discontinue drugs that act on the renin-angiotensin
system complicates the management of proteinuric pa-
tients (44,45).
Low-protein diets may represent a very interesting
therapeutic tool to contrast pregnancy-related hyperfil-
tration and reduce functional stress on remnant nephrons
(46). However, experience with low-protein diets in preg-
nancy is limited. Studies in vegans underline the safety
of this diet, provided that vitamin intake (mainly B12
and iron levels) and nutritional status are kept under
control (47–49). The few available animal studies, per-
formed on rats with genetic kidney diseases fed a soya-
enriched diet, suggest an advantage for the offspring
(32,33).
In this context, we planned our study, and the aimwas to
analyze the development of children born to mothers
affected by advanced or intensely proteinuric CKD who
followed a moderately protein-restricted vegan–vegetarian
diet in pregnancy. In an attempt to determine the effects of
the diet relative to the effects of global care, we identified a
control group of patients who were not on a diet for clin-
ical and/or logistic reasons (late referral, stable disease,
eating disorders, and cultural–logistic barriers) followed
in the same unit.
The main result was a significantly lower incidence of
SGA singleton babies in children born to mothers on the
diet: 3 of 21 singletons in the diet group versus 7 of 16
singletons in the control group (P=0.05). The overall inci-
dence was in line with the literature, which reports SGA
babies in the 10%–45% range in CKD (50,51).
In agreement with the absence of detrimental effects on
children’s growth, the growth data at 3 months to 10 years
were likewise supportive, with low hospitalization rates
and normal psychosocial development.
Within the limits of a nonrandomized study, which was
considered not ethically sound in pregnant women, the
results reassure us of the lack of negative long-term effects
on children’s growth both in utero and in the later follow-
up. Indeed, despite higher levels of proteinuria in the in-
tervention group, pregnancy and fetal outcomes did not
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differ and were actually even better for intrauterine
growth, which likely means a positive effect of the
diet (Tables 1–4).
This larger series confirms our previous data, which
targeted maternal outcomes (31). None of the patients
started dialysis during or within the first 3 months after
pregnancy, whereas only one diabetic patient in the in-
tervention group doubled her serum creatinine levels.
The neonatal death that was recorded (one preterm boy
twin affected by great vessel transposition who died on
day 6 of life from cerebral hemorrhage after cardiac
surgery) was presumably linked to diabetes, because
it had been detected before the development of ne-
phrotic syndrome and before the start of the diet.
Our pilot study has weakness and strengths. The first
limitation is the low number of cases with high hetero-
geneity in CKD stage and underlying disease. This limit
is particularly important in the analysis of the long-term
follow-up of the children. Nevertheless, our study
population represents, to the best of our knowledge,
the largest series ever reported of moderate protein
restriction in pregnant CKD patients.
The second limitation is the lack of randomization
and a perfectly matched control group. This bias re-
flects an ethical choice to allow patients to choose their
own diets during pregnancy, an issue that is shared
with long-term diet treatments (46). It is important to
point out that the control cohort, which mostly in-
cluded stage 3 CKD patients, may present two oppo-
site biases: a positive selection, because some patients
had milder disease (only one patient had diabetic ne-
phropathy, and baseline proteinuria was significantly
lower), and a negative selection because of late referral
or cultural and language barriers, often reflecting a
lower sociocultural status, which is itself linked with
less favorable outcomes. Nevertheless, neither GFR
nor any of the other baseline data differed between
groups. In contrast, proteinuria was higher in the
diet group, further underlining the importance of re-
sults obtained in a subset of cases with an a priori
poorer prognosis.
As a result of these limitations, our analysis supports
the lack of severe side effects of the diet, but it is not
powered enough to show a specific advantage in terms
of progression of renal impairment.
Finally, hyperfiltration is a complex issue in preg-
nancy, and only a dedicated study, with pre- and
postassessment of GFR after various meals, could
formally show a direct effect of the diet on this
parameter. This suggestion may set the ground for
additional pathophysiologic studies.
The main strength of this study is its novelty, because
it focuses on fetal and child growth as well as identi-
fication, within the limits mentioned above, of a com-
parable control group, at least for the decisions on the
timing of delivery.
Only larger multicenter studies and long-term follow-
up may solve the issues of efficacy and long-term advan-
tages. Also, they may identify uncommon side effects or
drawbacks of protein-restricted vegan–vegetarian diets in
pregnant women affected by advanced CKD, proteinuria,
or other kidney diseases.
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Pregnancy is a great challenge for CKD patients but a
major determinant of quality of life. In the context of the
limited literature data, our pilot study may support a
supplemented vegan–vegetarian diet as a safe option for
pregnant CKD patients, because it does not interfere with
intrauterine growth and may actually even facilitate it; fur-
thermore, it has no negative impact on child growth. Our
promising results, which were obtained in a field where
Figure 2. | Serumcreatinine and proteinuria at referral, delivery, and 3months after delivery. First point, referral; second point, delivery; third
point and dotted lines, 3 months after delivery. C, control; D, diet.
Table 4. Long-term follow-up of the children at least 6 months of age (17 children born to mothers on the diet and 12 children born to
mothers on unrestricted diets)
Age
Children with Height
and/or Weight Measurements
,3rd Centile According
to Cacciari-cdc
Hospitalizations
Children from on-
diet mothersa
17 2 years (3
months-10 years)
4/17 available cases Hospitalized at least once:
4/17 available cases
(intestinal infection;
pneumonia; orthopaedic
surgery -2 cases)
Children from
control mothersb
12 2 years (3
months – 9 years)
2/12 available cases Hospitalized at least once:
4/12 available cases (patent
Botallus; cyst excision; allergic
reaction; malaria)
P value (diet
versus controls)c
— 0.33 0.27
aChildren born tomotherswho followed the low-protein supplemented vegan diet for at least 4weeks in pregnancy. Updates available
in 17 children aged.3 months.
bChildren born to from mothers who followed a nonrestricted diet in pregnancy. Updates available in 12 children aged.3 months.
cSingletons.
8 Clinical Journal of the American Society of Nephrology
treatment options are very limited, should be the basis for
additional studies on this crucial, and so far, neglected issue.
Disclosures
None.
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